Alex Therapeutics and Navamedic Collaborate to Develop a Companion App for Parkinson’s Disease
Shots:
- Navamedic has entered into an exclusive agreement with Alex Therapeutics for developing a companion app to assist in Parkinson’s treatment management
- The app will be developed by Alex Therapeutics to assist those on Flexilev and provide medication management, supporting need of Parkinson’s disease patients
- The app complements OraFID, a next-generation dose dispenser that contains Flexilev, to help patients adhere to personalized treatment regimens. It will launch in Sweden, Norway & Denmark in 2025
Ref: Alex Therapeutics | Image: Alex Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
